MBX Biosciences
MBX
54.54
-2.38
-4.18%
MBX Biosciences
US · MBX
#2567 by market cap
Listed 2024
54.54
-2.38
-4.18%
Live - 5344 symbols - heartbeat 13s ago
· 2026-10-07 23:20
After-hours
54.32
-0.40%
Overnight
55.19
+1.19%
- Market cap
- 2.63B
- P/E (TTM)i
- -23.01
- P/Bi
- 6.41
- EPSi
- -2.38
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on MBX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 7 analysts
Buy
Avg price target
99.29 +82.0%
Price target rangecurrent 54.54
Low70.00
Avg99.29
High150.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-02 | Guggenheim | -- | BUY | 150.00 |
| 2026-08-21 | J.P. Morgan | -- | BUY | 88.00 |
| 2026-08-11 | Stifel | -- | BUY | 70.00 |
| 2026-08-10 | Truist Financial | -- | BUY | 88.00 |
| 2026-08-08 | LifeSci Capital | -- | BUY | 121.00 |
| 2026-08-07 | Barclays | -- | BUY | 88.00 |
| 2026-08-06 | LifeSci Capital | -- | BUY | 121.00 |
| 2026-07-24 | UBS | -- | BUY | 90.00 |
| 2026-07-23 | UBS | -- | BUY | 90.00 |
| 2026-07-15 | Truist Financial | -- | BUY | -- |
| 2026-07-14 | LifeSci Capital | -- | BUY | 91.00 |
| 2026-07-14 | Guggenheim | -- | BUY | 88.00 |
| 2026-06-18 | LifeSci Capital | -- | BUY | 91.00 |
| 2026-06-15 | Truist Financial | -- | BUY | 70.00 |
| 2026-06-15 | Guggenheim | -- | BUY | 88.00 |
| 2026-06-15 | Barclays | -- | BUY | 70.00 |
| 2026-06-13 | LifeSci Capital | -- | BUY | 91.00 |
| 2026-06-12 | LifeSci Capital | -- | BUY | 91.00 |
| 2026-06-11 | Truist Financial | -- | BUY | -- |
| 2026-06-10 | Barclays | -- | BUY | 70.00 |
| 2026-06-08 | LifeSci Capital | -- | BUY | 91.00 |
| 2026-05-16 | LifeSci Capital | -- | BUY | 91.00 |
| 2026-05-12 | Citizens JMP | -- | BUY | 86.00 |
| 2026-05-12 | Stifel | -- | BUY | 56.00 |
| 2026-05-12 | Barclays | -- | BUY | 70.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Buy
Analyst consensus
Buy
All 3 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-07 23:20:28 · For reference only, not investment advice and not tailored to your situation.